Washington, D.C. 20549










Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): February 17, 2012




Cytomedix, Inc.

(Exact name of registrant as specified in its charter)




Delaware 01-32518 23-3011702
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)


209 Perry Parkway, Suite 7, Gaithersburg, MD 20877

(Address of Principal Executive Office) (Zip Code)



(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events


On October 17, 2011, Cytomedix, Inc. (the “Company”) in a Current Report on Form 8-K (the “8-K”) announced, among other things, that it executed an option agreement related to the AutoloGel System. The contents of the 8-K are incorporated by reference herein. Subsequently, on February 2, 2012, the Company announced an extension of the exclusive option period until June 30, 2012 and the expected receipt of an additional $2.5 million non-refundable payment. The Company hereby confirms receipt of the payment in full on February 17, 2012 in connection with the extension of the agreement.


Item 9.01 Financial Statement and Exhibits





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


  Cytomedix, Inc.
  By:   /s/ Martin P. Rosendale

Martin P. Rosendale

Chief Executive Officer



Date: February 21, 2012